This clinical trial investigates the feasibility and safety of a portable exoskeleton device to improve mobility in patients with Parkinson's disease (PD). The study is sponsored by the VA Office of Research and Development, reflecting the significant burden of movement disorders among Veterans and the Department's commitment to developing innovative rehabilitation technologies[1][2].
Portable exoskeletons represent a promising frontier in neurorehabilitation for neurodegenerative diseases, offering device-based assistance that can be used in daily life settings rather than limited to clinical environments.
| Parameter | Value |
|---|---|
| NCT Number | NCT06028529 |
| Title | Portable Exoskeleton for Parkinson's Disease Mobility |
| Status | Not Yet Recruiting / Recruiting |
| Phase | Not Applicable (Feasibility Study) |
| Sponsor | VA Office of Research and Development |
| Mechanism | Device-based rehabilitation |
| Intervention | Portable exoskeleton device |
| Estimated Enrollment | Variable (typical feasibility: 20-50 participants) |
| Study Design | Single-group or randomized controlled trial |
The trial targets patients with:
Portable exoskeletons for Parkinson's disease operate through several mechanisms to improve mobility:
Parkinson's disease affects mobility through:
Traditional dopaminergic medications (levodopa, dopamine agonists) effectively treat resting tremor and bradykinesia but often incompletely address gait dysfunction and freezing of gait. Exoskeletons offer a complementary mechanical approach.
| Device Type | Mechanism | Advantages | Limitations |
|---|---|---|---|
| Portable Exoskeleton | Mechanical joint assistance | Ambulatory, daily use | Requires user tolerance |
| tDCS | Electrical brain modulation | Non-invasive | Session-based |
| CUE1 Device | Vibrotactile cueing | Wearable, continuous | Sensory-dependent |
| Virtual Reality | Visual/sensory cueing | Engaging | Fixed environment |
| Deep Brain Stimulation | Neural modulation | Effective for motor symptoms | Invasive, surgical |
Despite advances in Parkinson's disease pharmacology: